Earnings Release • Sep 15, 2009
Earnings Release
Open in ViewerOpens in native device viewer
| Summary | May - July | May - July | Change |
|---|---|---|---|
| SEK M | 2009/10 | 2008/09 | |
| Order bookings | 1,658 | 1,151 | 19%* |
| Net sales | 1,440 | 1,025 | 15%* |
| Operating profit | 89 | 13 | |
| Net profit | 56 | 1 | |
| Cash flow from operating | |||
| activities | -138 | -163 | |
| Earnings per share, | |||
| after dilution, SEK | 0.62 | 0.02 |
* Compared to the first quarter last fiscal year at unchanged exchange rates.
Demand for Elekta's clinical solutions, products and services remained strong in the first three months of 2009/10. Order bookings rose by 19 percent in local currency with solid performance in all regions. Net sales grew to SEK 1,440 M and operating result rose to SEK 89 M. Earnings per share improved to SEK 0.62 from SEK 0.02.
Demand increased for aftermarket services and software. Elekta provides services during the lifetime of the product and software for efficient workflow solutions, thereby making it possible for customers to focus on patient care. We continue to grow with our over 5,000 customers - an important element for Elekta's sustainable profitable growth.
Elekta is a leading provider of image guided radiotherapy, stereotactic radiotherapy and radiosurgery and oncology software. This year we are increasing investments in research and development to bring new and refined solutions to market for improved patient care and higher efficiency for healthcare providers.
At the end of July Elekta received FDA-clearance for VMAT in combination with the radiation treatment planning system Monaco. This is expected to lead to growing sales of VMAT towards the end of this year.
We are continuing to execute on our plan for geographical expansion. With a complete portfolio of products and solutions fulfilling the clinical demands, Elekta is in a strong position for future growth from new territories. In the quarter Elekta has added new partners offering financing solutions by signing agreements with Swedish Export Corporation, SEK, and Swedfund International AB. The aim is to improve availability for cancer care worldwide, and to seize the opportunities of growth for Elekta.
The economic downturn has so far had limited effect on investments in cancer care, but the uncertainty remains. It may become more difficult for private customers to obtain financing and future health care investments might be negatively affected.
Elekta's efficiency improvement program is proceeding according to plan. Restructuring costs amounted to SEK 11 M in the quarter. Annual savings from the program are expected at SEK 100 M with full effect next fiscal year. For 2009/10 the operating costs are expected to increase by around 5 percent in local currency.
Currency markets remained volatile in the quarter. We expect positive effect on results for this fiscal year at close to SEK 250 M at present currency rates.
Elekta's financial outlook remains unchanged of an increase in net sales by more than 8 percent in local currency, and operating profit increase in kronor of more than 35 percent. Net sales and operating profit are expected to be significantly higher in the second half of the year compared with the first.
Tomas Puusepp President and CEO
Demand for Elekta's clinical solutions, products and services was strong across all regions in the first quarter. Order bookings rose 44 percent to SEK 1,658 M (1,151). Based on unchanged exchange rates order bookings increased by 19 percent.
Rolling 12 months order bookings rose 38 percent to SEK 8,163 M.
Order backlog on July 31, 2009 was SEK 7,140 M compared to SEK 7,267 M on April 30, 2009. Order backlog is converted at closing exchange rates, which resulted in a negative translation difference of SEK 346 M.
| Order bookings | May - July | May - July | Change | Rolling | Change | May-April |
|---|---|---|---|---|---|---|
| SEK M | 2009/10 | 2008/09 | 12 months | 2008/09 | ||
| North and South America | 658 | 478 | 38% | 3,415 | 31% | 3,235 |
| Europe, Middle East, Africa | 615 | 401 | 53% | 2,856 | 29% | 2,642 |
| Asia Pacific | 385 | 272 | 42% | 1,892 | 78% | 1,779 |
| Group | 1,658 | 1,151 | 44% | 8,163 | 38% | 7,656 |
The North American market is primarily driven by rising cancer incidence and rapid acceptance of new and refined treatment methods. The US is the largest market for Elekta in the region. Following the financial crisis and economic downturn, sales cycles have become longer and there is a need for alternative financing. During the quarter CMS, Centers of Medicare and Medicaid Services, proposed changes in reimbursement rates for radiotherapy. For freestanding clinics major cuts are proposed for certain treatments while hospitals are proposed to receive increased reimbursement rates. It is possible that some freestanding clinics in the US will hold off investment decisions until the reimbursement levels are set in November.
Order bookings for the region rose 8 percent based on unchanged exchange rates during the first quarter compared to the same period last year. The growth was attributable to South America.
In the South American market there is a shortage of treatment capacity and lack of radiotherapists, oncologists and neurosurgeons. In the quarter Elekta received an order in Brazil of six linear accelerators and software for workflow solutions and radiation treatment planning.
CentraState Medical Center in the US became the first customer in the world to be equipped with both the two radiation treatment systems Elekta Axesse™ and Elekta Infinity. Both systems include the Elekta VMAT (Volumetric Modulated Arc Therapy) capability.
The contribution margin for region North and South America rose to 33 (30) percent. The improvement was mainly an effect of higher volume and positive currency effects.
The market development in Europe is to a large extent driven by national and regional initiatives to remedy the lack of radiation treatment capacity. The majority of treatment systems in Europe is procured through public tenders, facilitating transparent, yet relatively long sales processes. Elekta's ability to provide comprehensive and integrated solutions, based on open connectivity, makes the company an attractive partner. There is demand for modern information systems for cancer care, particularly for the purpose of improving productivity and multi-site connectivity, along with a high standard of patient care.
Order bookings for Region Europe including Middle East and Africa increased based on unchanged exchange rates by 34 percent compared to the same period last year. Demand was strong across the region.
The contribution margin rose to 30 (27) percent for the region. The improvement is due to product mix and positive currency effects.
There is a solid rationale for a continued long-term market growth in Asia. There is a lack of treatment capacity and the number of linear accelerators per capita is low by international comparison. Elekta is well positioned in the region to support health care providers.
China is an important growth market in the region and Elekta is the market leader for advanced radiation therapy solutions. The launch of Elekta Compact™ will provide means for improving availability of cancer care. The Chinese government has announced plans of investing USD 125 B in the healthcare sector. This is expected to have a positive impact on the availability of radiation treatment capacity.
Order bookings for Region Asia Pacific increased based on unchanged exchange rates by 14 percent. Demand was strong in most markets while order bookings in Japan were lower due to seasonality.
Product mix in Asia Pacific led to a lower contribution margin of 17 (24) percent.
Net sales rose 40 percent to SEK 1,440 M (1,025). Based on unchanged exchange rates net sales rose 15 percent.
| Net sales | May - July | May - July | Change | Rolling | Change | May-April |
|---|---|---|---|---|---|---|
| SEK M | 2009/10 | 2008/09 | 12 months | 2008/09 | ||
| North and South America | 630 | 420 | 50% | 2,919 | 38% | 2,709 |
| Europe, Middle East, Africa | 461 | 352 | 31% | 2,627 | 32% | 2,518 |
| Asia Pacific | 349 | 253 | 38% | 1,558 | 52% | 1,462 |
| Group | 1,440 | 1,025 | 40% | 7,104 | 38% | 6,689 |
Operating profit rose to SEK 89 M (13), positively impacted by higher volumes and positive currency effects.
Gross margin amounted to 45 percent (43). Operating margin was 6 percent (1).
Investments in research and development rose 30 percent to SEK 138 M (106) equal to 10 percent (10) of net sales. Capitalization of development costs and amortization of capitalized development costs affected earnings positively by SEK 7 M (pos. 7). Capitalization amounted to SEK 18 M (13) and amortization to SEK 11 M (6).
Elekta's efficiency improvement program is proceeding according to plan. Restructuring costs amounted to SEK 11 M in the quarter. Annual savings from the program are expected at SEK 100 M with full effect in 2010/11.
Calculated IFRS 2 costs for Elekta's outstanding option program amounted to SEK 9 M (13).
In total, exchange fluctuations affected operating profit compared with previous year positively with approximately SEK 53 M.
Exchange rate gains from forward contracts in operating profit were SEK 54 M (gains 7). Unrealized exchange rate gains from cash flow hedges amounted to SEK 128 M and are reported in shareholders' equity taking into account the tax impact. Elekta's currency hedging policy is based on anticipated sales in foreign currency up to 24 months.
Net financial items amounted to an expense of SEK 6 M (expense 11). Net interest expenses improved to SEK 11 M (18), impacted by a decreased average interest rate and a lower net debt.
Profit after financial items amounted to SEK 83 M (2). Tax expense amounted to SEK 27 M or 32 percent. Profit after taxes amounted to SEK 56 M (1).
Earnings per share amounted to SEK 0.62 (0.02) before dilution and SEK 0.62 (0.02) after dilution.
Return on shareholders' equity amounted to 27 percent (22) and return on capital employed was 25 percent (24).
Investment in intangible and tangible fixed assets amounted to SEK 49 M (22). Amortization of intangible and depreciation of tangible fixed assets amounted to SEK 56 M (47).
Due to the seasonal build-up of working capital as well as the high level of paid tax, cash flow from operating activities was negative SEK 138 M (neg. 163). Cash flow after investments was negative SEK 164 M (neg. 221).
As a consequence of debt repayment and negative cash flow liquid funds decreased to SEK 477 M compared to SEK 828 M on April 30, 2009, and interest bearing liabilities decreased to SEK 1,371 M compared with SEK 1,627 M on April 30, 2009. Net debt amounted to SEK 894 M compared with SEK 799 M on April 30, 2009. Net debt/equity ratio was 0.33.
Total number of shares on August 31, 2009 was 92,124,563 divided between 3,562,500 Ashares and 88,562,063 B-shares.
The average number of employees was 2,461 (2,390). The average number of employees in the Parent Company was 23 (20).
The number of employees on July 31, 2009 totaled 2,471 compared with 2,509 on April 30, 2009.
The global financial crisis and economic downturn constitute a risk. The worldwide recession might mean less availability of finance for private customers and reduced future health care spending. Elekta's ability to deliver treatment equipment is, to a large extent, dependent on customers being able to accept delivery in the agreed timeframe, which results in a risk of delayed deliveries and corresponding delayed revenue recognition. In its operations, Elekta is subject to a number of financial risks, primarily related to exchange rate fluctuations.
Description of risks and uncertainties in Elekta's business can be found in the annual report 2008/09 on page 36 and in note 2. Nothing essential has happened to change the risks described therein.
In fiscal year 2009/10, Elekta's net sales are expected to grow by more than 8 percent in local currency. Elekta's operating profit in SEK is expected to grow by more than 35 percent.
Net sales and operating profit are also for fiscal year 2009/10 expected to be significantly higher in the second half of the year compared with the first.
Stockholm, September 15, 2009
Elekta AB (publ)
Tomas Puusepp President and CEO
The Company's auditors have not reviewed this interim report.
6 month interim report May-October 2009/10 December 10, 2009
Tomas Puusepp, President and CEO, Elekta AB (publ) Tel: +46 8 587 25 520, e-mail: [email protected]
Håkan Bergström, CFO, Elekta AB (publ) Tel: +46 8 587 25 547, e-mail: [email protected]
Stina Thorman, Investor Relations, Elekta AB (publ) Tel: +46 8 587 25 437, e-mail: [email protected]
Elekta AB (publ) Corporate registration number 556170-4015 Box 7593, SE 103 93 Stockholm, Sweden
This interim report is prepared according to IAS 34 and recommendation RFR 1.1 of the Swedish Financial Reporting Board, and with regard to the Parent Company, also according to RFR 1.2. The accounting principles applied correspond to those presented in the 2008/09 Annual Report. These include:
• Introduction of changes in IAS 1 Presentation of financial statements. Format and design of the financial statements have been changed.
• IFRS 8 Operating segments that replaces IAS 14. According to IFRS 8 segment information must be reported on the basis of how management internally follows up operations.
| Exchange rates | Average rate | Closing rate | ||||||
|---|---|---|---|---|---|---|---|---|
| May-Jul. | May-Jul. Change | Jul. 31, | Apr. 30, Change | |||||
| Country | Currency | 2009/10 | 2008/09 | 2009 | 2009 | |||
| Euro | 1 EUR | 10.765 | 9.384 | 15% | 10.398 | 10.663 | -2% | |
| Great Britain | 1 GBP | 12.412 | 11.841 | 5% | 12.205 | 11.880 | 3% | |
| Japan | 100 JPY | 8.071 | 5.668 | 42% | 7.735 | 8.175 | -5% | |
| United States | 1 USD | 7.738 | 6.004 | 29% | 7.370 | 7.985 | -8% |
Order bookings and net sales are accounted at average exchange rates for the reporting period while order backlog and balance sheet items are accounted at closing exchange rates.
| 3 months | 3 months | 12 months | 12 months | |
|---|---|---|---|---|
| SEK M | May - July 2009/10 |
May - July 2008/09 |
Aug. - July 2008/09 |
May - Apr. 2008/09 |
| Net sales Cost of products sold |
1,440 -798 |
1,025 -587 |
7,104 -3,869 |
6,689 -3,658 |
| Gross income | 642 | 438 | 3,235 | 3,031 |
| Selling expenses | -248 | -197 | -984 | -933 |
| Administrative expenses | -171 | -140 | -673 | -642 |
| R&D expenses Exchange differences in operations |
-131 -3 |
-99 11 |
-517 -155 |
-485 -141 |
| Operating profit | 89 | 13 | 906 | 830 |
| Result from participations | ||||
| in associated companies | 2 | -2 | 5 | 1 |
| Interest income | 3 | 5 | 21 | 23 |
| Interest expenses Financial exchange differences |
-14 3 |
-23 9 |
-98 21 |
-107 27 |
| Income after financial items | 83 | 2 | 855 | 774 |
| Taxes | -27 | -1 | -254 | -228 |
| Net income | 56 | 1 | 601 | 546 |
| Attributable to | ||||
| Parent Company shareholders | 58 | 2 | 608 | 552 |
| Minority shareholders | - 2 | - 1 | - 7 | - 6 |
| Earnings per share before dilution | 0.62 | 0.02 | 6.60 | 6.00 |
| Earnings per share after dilution | 0.62 | 0.02 | 6.60 | 6.00 |
| Income/costs reported directly against | ||||
| shareholders' equity IFRS 2 cost |
7 | 8 | 24 | 25 |
| IAS 39 unrealized cash flow hedges | 173 | - 7 | 129 | - 51 |
| Translation of subsidiaries and associated companies | - 58 | 9 | 232 | 299 |
| Translation of loans for equity hedge | 0 | 6 | 53 | 59 |
| Income tax relating to components of other | ||||
| comprehensive income Other comprehensive income for the period |
- 48 74 |
- 6 10 |
- 51 387 |
- 9 323 |
| Comprehensive income for the period | 130 | 11 | 988 | 869 |
| Attributable to | ||||
| Parent Company shareholders | 132 | 12 | 992 | 872 |
| Minority shareholders | - 2 | - 1 | - 4 | - 3 |
| CASH FLOW | ||||
| Operating cash flow | 27 | -18 | 782 | 737 |
| Change in working capital | -165 | -145 | -17 | 3 |
| Cash flow from operating activities | -138 | -163 | 765 | 740 |
| Investments and disposals | -26 | -58 | -128 | -160 |
| Cash flow after investments | -164 | -221 | 637 | 580 |
| External financing | -171 | 15 | -425 | -239 |
| Change in liquid funds | -351 | -205 | 280 | 426 |
| July 31, | July 31, | April 30, | |
|---|---|---|---|
| SEK M | 2009 | 2008 | 2009 |
| Intangible assets | 2,977 | 2,658 | 3,150 |
| Tangible fixed assets | 252 | 219 | 265 |
| Shares and long-term receivables | 53 | 35 | 59 |
| Deferred tax assets | 30 | 14 | 34 |
| Inventories | 584 | 593 | 553 |
| Receivables | 3,180 | 2,422 | 3,062 |
| Liquid funds | 477 | 197 | 828 |
| Total assets | 7,553 | 6,138 | 7,951 |
| Elektas owners' equity | 2,681 | 1,846 | 2,549 |
| Minority interest | 4 | 8 | 6 |
| Shareholders' equity | 2,685 | 1854 | 2,555 |
| Interest-bearing liabilities | 1,371 | 1,434 | 1,627 |
| Interest-free liabilities | 3,497 | 2,850 | 3,769 |
| Total shareholders' equity and liabilities | 7,553 | 6,138 | 7,951 |
| Assets pledged | 1 | 1 | 1 |
| Contingent liabilities | 88 | 66 | 75 |
| July 31, | July 31, | April 30, | |
|---|---|---|---|
| SEK M | 2009 | 2008 | 2009 |
| Attributable to Elekta's owners | |||
| Opening balance | 2,549 | 1,804 | 1,804 |
| Comprehensive earnings for the period | 132 | 12 | 872 |
| Exercise of warrants | 30 | 34 | |
| Dividend | -161 | ||
| Closing balance | 2,681 | 1,846 | 2,549 |
| Minority intrest | |||
| Opening balance | 6 | 9 | 9 |
| Comprehensive earnings for the period | -2 | -1 | -3 |
| Closing balance | 4 | 8 | 6 |
| Closing balance | 2,685 | 1,854 | 2,555 |
| KEY FIGURES | 12 months May - Apr. 2004/05* |
12 months May - Apr. 2005/06 |
12 months May - Apr. 2006/07 |
12 months May - Apr. 2007/08 |
12 months May - Apr. 2008/09 |
3 months May - July 2008/09 |
3 months May - July 2009/10 |
|---|---|---|---|---|---|---|---|
| Order bookings, SEK M | 3,558 | 4,705 | 5,102 | 5,882 | 7,656 | 1,151 | 1,658 |
| Net sales, SEK M | 3,152 | 4,421 | 4,525 | 5,081 | 6,689 | 1,025 | 1,440 |
| Operating result, SEK M | 364 | 453 | 509 | 650 | 830 | 13 | 89 |
| Operating margin | 12% | 10% | 11% | 13% | 12% | 1% | 6% |
| Profit margin | 12% | 10% | 11% | 12% | 12% | 0% | 6% |
| Shareholders' equity, SEK M | 1,694 | 1,868 | 1,863 | 1,813 | 2,555 | 1,854 | 2,685 |
| Capital employed, SEK M | 2,527 | 2,959 | 2,850 | 3,262 | 4,182 | 3,288 | 4,056 |
| Equity/assets ratio | 38% | 35% | 35% | 29% | 32% | 30% | 36% |
| Net debt/equity ratio | 0.05 | 0.06 | 0.27 | 0,58 | 0,31 | 0,67 | 0,33 |
| Return on shareholders' equity | 16% | 17% | 19% | 23% | 27% | 22% | 27% |
| Return on capital employed | 21% | 18% | 20% | 24% | 24% | 24% | 25% |
* Restated according to IFRS.
** Based on rolling 12 months.
| DATA PER SHARE | 12 months | 12 months | 12 months | 12 months | 12 months | 3 months | 3 months |
|---|---|---|---|---|---|---|---|
| May - Apr. | May - Apr. | May - Apr. | May - Apr. | May - Apr. | May - July | May - July | |
| 2004/05* | 2005/06 | 2006/07 | 2007/08 | 2008/09 | 2008/09 | 2009/10 | |
| Earnings per share | |||||||
| before dilution, SEK | 2.69 | 3.23 | 3.72 | 4.46 | 6.00 | 0.02 | 0,62 |
| after dilution, SEK | 2.69 | 3.21 | 3.70 | 4.44 | 6.00 | 0.02 | 0,62 |
| Cash flow per share | |||||||
| before dilution, SEK | -11.09 | 1.68 | -1.14 | -3.04 | 6.30 | -2.41 | -1,78 |
| after dilution, SEK | -11.06 | 1.67 | -1.14 | -3.03 | 6.30 | -2.41 | -1,78 |
| Shareholders' equity per share | |||||||
| before dilution, SEK | 18.02 | 19.80 | 19.96 | 19.70 | 27.67 | 20.04 | 29,10 |
| after dilution, SEK | 18.84 | 20.45 | 20.46 | 20.03 | 27.67 | 22.04 | 29,10 |
| Average number of shares | |||||||
| before dilution, 000s | 93,991 | 94,136 | 93,698 | 92,199 | 92,029 | 91,747 | 92,125 |
| after dilution, 000s | 94,182 | 94,785 | 94,249 | 92,479 | 92,029 | 91,763 | 92,125 |
| Number of shares at closing | |||||||
| before dilution, 000s | 94,028 | 94,332 | 93,036 | 91,570 | 92,125 | 92,125 | 92,125 |
| after dilution, 000s | 95,703 | 95,703 | 94,072 | 92,245 | 92,125 | 93,933 | 92,125 |
* Restated according to IFRS.
Dilution in 2004/05-2007/08 refers to warrants program 2004/2008.
All historical data restated for split 3:1 October 2005.
| Data per quarter | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 |
|---|---|---|---|---|---|---|---|---|---|
| SEK M | 2007/08 | 2007/08 | 2007/08 | 2007/08 | 2008/09 | 2008/09 | 2008/09 | 2008/09 | 2009/10 |
| Order bookings | 1,136 | 1,336 | 1,229 | 2,181 | 1,151 | 1,672 | 1,661 | 3,172 | 1,658 |
| Net sales | 975 | 1,213 | 1,097 | 1,796 | 1,025 | 1,467 | 1,664 | 2,533 | 1,440 |
| Operating profit | 36 | 159 | 72 | 383 | 13 | 105 | 191 | 521 | 89 |
| Cash flow from | |||||||||
| operating activities | -28 | 168 | -51 | 230 | -163 | 68 | 2 | 833 | -138 |
Elekta applies geographical segmentation. Order bookings, net sales and contribution margin for respective region are reported to Elekta's CEO and CFO (chief operating decision makers). In the regions operating expenses are cost of products sold and expenses directly attributable to the respective region reported. Global costs for R&D, marketing, management of product supply centers and Parent Company are not allocated per region. Currency exposure is concentrated to product supply centers. The majority of currency exchange differences are reported in global costs.
| Segment reporting May-July 2009/10 | |
|---|---|
| SEK M | North and South America |
Europe, Africa and Middle East |
Asia Pacific | Total | % of net sales |
|---|---|---|---|---|---|
| Net sales | 630 | 461 | 349 | 1,440 | |
| Operating expenses | -420 | -325 | -290 | -1,035 | -72% |
| Contribution margin | 210 | 136 | 59 | 405 | 28% |
| Global costs | -316 | -22% | |||
| Operating result | 89 | 6% | |||
| Contribution margin | 33% | 30% | 17% |
| SEK M | North and South America |
Europe, Africa and Middle East |
Asia Pacific | Total | % of net sales |
|---|---|---|---|---|---|
| Net sales | 420 | 352 | 253 | 1,025 | |
| Operating expenses | -296 | -257 | -193 | -746 | -73% |
| Contribution margin | 124 | 95 | 60 | 279 | 27% |
| Global costs | -266 | -26% | |||
| Operating result | 13 | 1% | |||
| Contribution margin | 30% | 27% | 24% |
| North and | Europe, Africa | Asia Pacific | Total | % of | |
|---|---|---|---|---|---|
| SEK M | South America | and Middle East | net sales | ||
| Net sales | 2,709 | 2,518 | 1,462 | 6,689 | |
| Operating expenses | -1,749 | -1,590 | -1,069 | -4,408 | -66% |
| Contribution margin | 960 | 928 | 393 | 2,281 | 34% |
| Global costs | -1,451 | -22% | |||
| Operating result | 830 | 12% | |||
| Contribution margin | 35% | 37% | 27% |
| SEK M | North and South America |
Europe, Africa and Middle East |
Asia Pacific | Total | % of net sales |
|---|---|---|---|---|---|
| Net sales | 2,919 | 2,627 | 1,558 | 7,104 | |
| Operating expenses | -1,873 | -1,658 | -1,166 | -4,697 | -70% |
| Contribution margin | 1,046 | 969 | 392 | 2,407 | 36% |
| Global costs | -1,501 | -22% | |||
| Operating result | 906 | 14% | |||
| Contribution margin | 36% | 37% | 25% |
Elekta's operations are characterized by significant quarterly variations in delivery volumes, which have a direct impact on net sales and profits. This is accentuated when the operation is split into segments as is the impact of currency fluctuations between the years.
Improvement in contribution margin during the first quarter in region North and South America is primarily driven by the strengthening of the US-dollar against Swedish kronor and British pounds as well as higher volume. For region Europe, Middle East and Africa the improvement is a result of product mix and the strengthening of the Euro against Swedish kronor and British pounds. Product mix in Asia Pacific reduced the contribution margin despite a favorable currency impact.
| May - July | May - July | |
|---|---|---|
| SEK M | 2009/10 | 2008/09 |
| Administrative expenses | -20 | -19 |
| Financial items | -1 | -8 |
| Income after financial items | -21 | -27 |
| Taxes | 6 | 8 |
| July 31, | April 30, | |
|---|---|---|
| SEK M | 2009 | 2009 |
| Financial fixed assets | 1,543 | 1,541 |
| Current assets | 1,556 | 1,840 |
| Total assets | 3,099 | 3,381 |
| Shareholders' equity | 1,191 | 1,205 |
| Untaxed reserve | 37 | 37 |
| Long-term liabilities | 1,290 | 1,530 |
| Short-term liabilities | 581 | 609 |
| Total shareholders' equity and liabilities | 3,099 | 3,381 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.